Design of targeted dosage form of ofloxacin
The targeted pro-drug is a classical pro-drug design often representing a non-specific chemical approach to mask undesirable drug properties, such as limited bioavailability, lack of site specificity, and chemical instability. On the other hand, targeted pro-drug design represents a new strategy for...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Serbian Chemical Society
2006-12-01
|
Series: | Journal of the Serbian Chemical Society |
Subjects: | |
Online Access: | http://www.shd.org.yu/HtDocs/SHD/Vol71/No12/JSCS_V71_No12-03.pdf |
id |
doaj-a5bd5f543aa3435e865d0a0c93d4a466 |
---|---|
record_format |
Article |
spelling |
doaj-a5bd5f543aa3435e865d0a0c93d4a4662020-11-25T00:19:14ZengSerbian Chemical Society Journal of the Serbian Chemical Society0352-51392006-12-01711212691273Design of targeted dosage form of ofloxacinE. MANOGRANM. ASHRAF ALIA. AHAMED SIDDIQUIM. SHAHAR YARThe targeted pro-drug is a classical pro-drug design often representing a non-specific chemical approach to mask undesirable drug properties, such as limited bioavailability, lack of site specificity, and chemical instability. On the other hand, targeted pro-drug design represents a new strategy for directed and efficient drug delivery. Quinolone antibiotics exert their pharmacological effect by inhibiting the cell wall synthesis of the pathogen. However, development of resistance exists, which instigates for a new higher congener to remain in clinical practice. To overcome this phenomenon and also to produce site-specific activity of the cell walls of the pathogen, ofloxacin is conjugated with a hydroxypropyl methacrylamide polymer backbone moiety. The results of in vitro release studies indicate the possibilities for the development of a new drug for site-specific therapy with an improved t1/2 of the drug. This novel pro-drugmay have opened a new vista in antibiotic chemotherapy.http://www.shd.org.yu/HtDocs/SHD/Vol71/No12/JSCS_V71_No12-03.pdfofloxacinhydroxypropyl methacrylamidebioavailabilitypro-drug |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
E. MANOGRAN M. ASHRAF ALI A. AHAMED SIDDIQUI M. SHAHAR YAR |
spellingShingle |
E. MANOGRAN M. ASHRAF ALI A. AHAMED SIDDIQUI M. SHAHAR YAR Design of targeted dosage form of ofloxacin Journal of the Serbian Chemical Society ofloxacin hydroxypropyl methacrylamide bioavailability pro-drug |
author_facet |
E. MANOGRAN M. ASHRAF ALI A. AHAMED SIDDIQUI M. SHAHAR YAR |
author_sort |
E. MANOGRAN |
title |
Design of targeted dosage form of ofloxacin |
title_short |
Design of targeted dosage form of ofloxacin |
title_full |
Design of targeted dosage form of ofloxacin |
title_fullStr |
Design of targeted dosage form of ofloxacin |
title_full_unstemmed |
Design of targeted dosage form of ofloxacin |
title_sort |
design of targeted dosage form of ofloxacin |
publisher |
Serbian Chemical Society |
series |
Journal of the Serbian Chemical Society |
issn |
0352-5139 |
publishDate |
2006-12-01 |
description |
The targeted pro-drug is a classical pro-drug design often representing a non-specific chemical approach to mask undesirable drug properties, such as limited bioavailability, lack of site specificity, and chemical instability. On the other hand, targeted pro-drug design represents a new strategy for directed and efficient drug delivery. Quinolone antibiotics exert their pharmacological effect by inhibiting the cell wall synthesis of the pathogen. However, development of resistance exists, which instigates for a new higher congener to remain in clinical practice. To overcome this phenomenon and also to produce site-specific activity of the cell walls of the pathogen, ofloxacin is conjugated with a hydroxypropyl methacrylamide polymer backbone moiety. The results of in vitro release studies indicate the possibilities for the development of a new drug for site-specific therapy with an improved t1/2 of the drug. This novel pro-drugmay have opened a new vista in antibiotic chemotherapy. |
topic |
ofloxacin hydroxypropyl methacrylamide bioavailability pro-drug |
url |
http://www.shd.org.yu/HtDocs/SHD/Vol71/No12/JSCS_V71_No12-03.pdf |
work_keys_str_mv |
AT emanogran designoftargeteddosageformofofloxacin AT mashrafali designoftargeteddosageformofofloxacin AT aahamedsiddiqui designoftargeteddosageformofofloxacin AT mshaharyar designoftargeteddosageformofofloxacin |
_version_ |
1725372552062173184 |